The Louisiana State University Health Sciences Center-Shreveport last week finalized a licensing agreement with Massachusetts drug developer Aphios, allowing the company to develop the compound bryostatin-1 as a possible localized treatment for organ transplant rejection.

The deal is a result of a nearly three-year research partnership between Aphios and LSUHSC-S, and is the latest product of a concerted effort at LSUHSC-S to ramp up collaboration between its faculty and industry, a school official told BTW this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Nov
14
Sponsored by
PerkinElmer

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions.